Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Treasury Shares for 9 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 4.89% to $9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 4.89% decrease, with the full-year FY2025 number at $9.1 million, down 4.89% from a year prior.
  • Treasury Shares was $9.1 million for Q4 2025 at Iovance Biotherapeutics, down from $9.9 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $12.2 million in Q1 2025 to a low of $3.5 million in Q4 2023.
  • A 3-year average of $8.4 million and a median of $9.7 million in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 208.93% in 2024, then decreased 4.89% in 2025.
  • Iovance Biotherapeutics' Treasury Shares stood at $3.5 million in 2023, then soared by 176.43% to $9.5 million in 2024, then dropped by 4.89% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Treasury Shares are $9.1 million (Q4 2025), $9.9 million (Q3 2025), and $11.4 million (Q2 2025).